Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.

Company profile
Ticker
VCEL
Exchange
Website
CEO
Dominick Colangelo
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne • Denali Therapeutics ...
Former names
AASTROM BIOSCIENCES INC
SEC CIK
Corporate docs
Subsidiaries
Marrow Donation, LLC • Vericel Denmark ApS • Vericel Security Corporation ...
IRS number
943096597
VCEL stock data
News

Looking Into Vericel's Return On Capital Employed
10 Aug 22
FDA Accepts MediWound's Refiling For Severe Thermal Burns Therapy For Review
3 Aug 22
Vericel: Q2 Earnings Insights
3 Aug 22
MediWound Announces U.S. FDA Acceptance Of Biologics License Application For NexoBrid For The Treatment Of Severe Thermal Burns
3 Aug 22
Earnings Scheduled For August 3, 2022
3 Aug 22
Press releases
Vericel Reports Second Quarter 2022 Financial Results
3 Aug 22
MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
3 Aug 22
Vericel Announces Publication of Positive Results from Retrospective Study by the Burn and Reconstructive Centers of America (BRCA) of Patients with Large Posterior Trunk Burns Treated with Epicel
21 Jul 22
Analyst ratings and price targets
Investment data
Securities sold
Number of investors
Calendar
3 Aug 22
12 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 62.24M | 62.24M | 62.24M | 62.24M | 62.24M | 62.24M |
Cash burn (monthly) | (no burn) | (no burn) | 3.03M | 1.43M | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 4.38M | 2.06M | n/a | n/a |
Cash remaining | n/a | n/a | 57.86M | 60.17M | n/a | n/a |
Runway (months of cash) | n/a | n/a | 19.1 | 42.2 | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Jun 22 | Lisa Wright | Common Stock | Option exercise | Acquire M | No | No | 0 | 433 | 0 | 2,784 |
1 Jun 22 | Lisa Wright | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 433 | 0 | 867 |
29 Apr 22 | Gilman Steven C | Common Stock | Sell | Dispose S | No | Yes | 30.94 | 900 | 27.85K | 5,200 |
27 Apr 22 | Rubino Alan L | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,600 | 0 | 11,994 |
27 Apr 22 | Rubino Alan L | Stock Option Common Stock | Grant | Acquire A | No | No | 31.99 | 6,500 | 207.94K | 6,500 |
27 Apr 22 | Rubino Alan L | RSU Common Stock | Grant | Acquire A | No | No | 0 | 2,600 | 0 | 2,600 |
27 Apr 22 | Rubino Alan L | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,600 | 0 | 0 |
27 Apr 22 | Hagen Heidi | Common Stock | Option exercise | Acquire M | No | No | 0 | 2,600 | 0 | 12,850 |
27 Apr 22 | Hagen Heidi | Stock Option Common Stock | Grant | Acquire A | No | No | 31.99 | 6,500 | 207.94K | 6,500 |
27 Apr 22 | Hagen Heidi | RSU Common Stock | Grant | Acquire A | No | No | 0 | 2,600 | 0 | 2,600 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 196 |
Opened positions | 34 |
Closed positions | 21 |
Increased positions | 68 |
Reduced positions | 71 |
13F shares | Current |
---|---|
Total value | 2.05B |
Total shares | 55.82M |
Total puts | 41K |
Total calls | 30.9K |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 7.11M | $271.57M |
Brown Capital Management | 6.11M | $233.54M |
RTW Investments | 4.02M | $153.55M |
Alger Associates | 3.2M | $0 |
Vanguard | 3M | $114.83M |
STT State Street | 2.94M | $112.46M |
Fred Alger Management | 2.76M | $105.36M |
Conestoga Capital Advisors | 2.6M | $99.25M |
FHI Federated Hermes | 1.62M | $62.1M |
MCQEF Macquarie | 1.52M | $58.23M |
Financial report summary
?Competition
ThermoGenesis • BioCardia • Athersys • Ocugen • Cellular Biomedicine • Regenicin • MyoKardia • Biostage • AVITA MedicalContent analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
assessing, Bank, bear, borrow, borrower, borrowing, Chase, China, commodity, conflict, covenant, desired, educational, escalation, external, geopolitical, globe, impossible, inflation, inflationary, instability, invasion, JPMorgan, labor, leverage, likelihood, loan, magnify, outstanding, physician, ratio, recent, revolving, Russia, Russian, senior, SOFR, Ukraine, vast
Removed:
administered, agency, emerged, fallen, learn, pathway, periodically, present, risen, sustained, transmission, updated, varied, world
Financial reports
Current reports
8-K
Vericel Reports Second Quarter 2022 Financial Results
3 Aug 22
8-K
Entry into a Material Definitive Agreement
2 Aug 22
8-K
Vericel Reports First Quarter 2022 Financial Results
4 May 22
8-K
Departure of Directors or Certain Officers
29 Apr 22
8-K
Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer
24 Feb 22
8-K
Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance
24 Feb 22
8-K
Entry into a Material Definitive Agreement
2 Feb 22
8-K
Advanced Therapies for the Sports Medicine and Severe Burn Care Markets CORPORATE PRESENTATION JANUARY 2022
12 Jan 22
8-K
Vericel Reports Third Quarter 2021 Financial Results
9 Nov 21
8-K
Entry into a Material Definitive Agreement
27 Aug 21
Registration and prospectus
S-8 POS
Registration of securities for employees (post-effective amendment)
6 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
6 May 22
S-8
Registration of securities for employees
6 May 22
S-3ASR
Automatic shelf registration
26 Aug 21
8-A12B/A
Registration of securities on exchange (amended)
12 Feb 21
S-8
Registration of securities for employees
6 Aug 20
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 19
S-8 POS
Registration of securities for employees (post-effective amendment)
1 May 19
Other
CT ORDER
Confidential treatment order
18 Jan 22
UPLOAD
Letter from SEC
18 Nov 19
CORRESP
Correspondence with SEC
12 Nov 19
UPLOAD
Letter from SEC
4 Nov 19
CT ORDER
Confidential treatment order
28 Nov 18
EFFECT
Notice of effectiveness
27 Aug 18
UPLOAD
Letter from SEC
27 Aug 18
CORRESP
Correspondence with SEC
23 Aug 18
CT ORDER
Confidential treatment order
6 Jun 18
CT ORDER
Confidential treatment order
5 Apr 18
Ownership
4
Vericel / LISA WRIGHT ownership change
2 Jun 22
4
Vericel / STEVEN C GILMAN ownership change
2 May 22
4
Vericel / LISA WRIGHT ownership change
29 Apr 22
4
Vericel / ROBERT L MD ZERBE ownership change
29 Apr 22
4
Vericel / Paul K Wotton ownership change
29 Apr 22
4
Vericel / STEVEN C GILMAN ownership change
29 Apr 22
4
Vericel / KEVIN F MCLAUGHLIN ownership change
29 Apr 22
4
Vericel / Alan L Rubino ownership change
29 Apr 22
4
Vericel / Heidi Hagen ownership change
29 Apr 22
4
Vericel / JONATHAN SIEGAL ownership change
11 Mar 22
Transcripts
2022 Q2
Earnings call transcript
3 Aug 22
2022 Q1
Earnings call transcript
4 May 22
2021 Q4
Earnings call transcript
24 Feb 22
2021 Q3
Earnings call transcript
9 Nov 21
2021 Q2
Earnings call transcript
4 Aug 21
2021 Q1
Earnings call transcript
6 May 21
2020 Q4
Earnings call transcript
24 Feb 21
2020 Q3
Earnings call transcript
5 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
5 May 20
Reddit threads
Daily Discussion Thread - August 3rd, 2022
3 Aug 22
Daily Discussion Thread - August 2nd, 2022
2 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Daily Discussion Thread - May 4th, 2022
4 May 22
Daily Discussion Thread - May 3rd, 2022
3 May 22
Daily Discussion Thread - May 2nd, 2022
2 May 22
Picks for 2022-02-25
25 Feb 22
Daily Discussion Thread - February 24th, 2022
24 Feb 22
Daily Discussion Thread - February 23rd, 2022
23 Feb 22
Daily Discussion Thread - February 22nd, 2022
22 Feb 22